Followup to this post: A US District Court has ruled that Myriad Genetic's patents on breast cancer genes BRCA1 and BRCA2, which allow them to hold exclusive rights to a widely used genetic test for inherited breast and ovarian cancer susceptibility, are invalid. Genomics Law Report analyzes the ruling in two posts. The decision is likely to be challenged in a legal appeal — but if upheld, it could have huge implications for the biotechnology industry. [more inside]
posted by zarq
on Mar 31, 2010 -
51 comments
Boy meets girl, you know how it goes. The catch? They're made from Myriad Pro. This short TED talk by someone called Rives was cute, and whimsical enough to make me smile. [more inside]
posted by oxford blue
on Nov 1, 2008 -
18 comments